We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01073553
First Posted: February 23, 2010
Last Update Posted: April 3, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Corporación Bonima S.A. de C.V.
Information provided by (Responsible Party):
Bayer
February 22, 2010
February 23, 2010
April 3, 2015
October 2009
October 2009   (Final data collection date for primary outcome measure)
  • Least square estimator of average maximum plasmatic concentration (log transformed) [ Time Frame: After two months ]
  • Least square estimator of area under the pharmacokinetic curve (log transformed) [ Time Frame: After two months ]
Same as current
Complete list of historical versions of study NCT01073553 on ClinicalTrials.gov Archive Site
  • Time at which maximum concentration is reached [ Time Frame: After two months ]
  • Area under the pharmacokinetic curve from time=0 to last blood sample [ Time Frame: After two months ]
  • Clearance constant of plasmatic concentration of study drug [ Time Frame: After two months ]
  • Half life of plasmatic concentration of study drug [ Time Frame: After two months ]
  • Adverse events collection [ Time Frame: Up to six weeks ]
Same as current
Not Provided
Not Provided
 
Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules
Prospective, Randomized, Open Label, Crossover Study to Compare the Bioavailability Between Optocef (Cephalexin 500 mg Capsules) From Bayer and Keflex (Cephalexin 250 mg Capsules) From Eli Lilly po in Healthy Subjects Using Equivalent Concentrations
A single dose, two treatments (two cephalexin capsules brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Anti-Infective Agents
  • Drug: Cephalexin capsules (Optocef, BAYO5448 )
    Single dose of 500 mg (One 500 mg capsule)
  • Drug: Cephalexin capsules (Keflex)
    Single dose of 500 mg (Two 250 mg capsules)
  • Experimental: Arm 1
    Intervention: Drug: Cephalexin capsules (Optocef, BAYO5448 )
  • Active Comparator: Arm 2
    Intervention: Drug: Cephalexin capsules (Keflex)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26
October 2009
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male or female volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis

Exclusion Criteria:

  • History of illnesses or any organic abnormalities that could affect the results of the study
  • History of tobacco or alcohol abuse or regular use of recreational or therapeutic drugs
  • Subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Mexico
 
 
NCT01073553
14784
No
Not Provided
Not Provided
Bayer
Bayer
Corporación Bonima S.A. de C.V.
Study Director: Bayer Study Director Bayer
Bayer
April 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP